EPS for Tetraphase Pharmaceuticals, Inc. (TTPH) Expected At $-0.64

February 15, 2018 - By Peter Erickson

 EPS for Tetraphase Pharmaceuticals, Inc. (TTPH) Expected At $ 0.64
Investors sentiment increased to 2.21 in Q3 2017. Its up 0.90, from 1.31 in 2017Q2. It increased, as 10 investors sold Tetraphase Pharmaceuticals, Inc. shares while 14 reduced holdings. 19 funds opened positions while 34 raised stakes. 29.38 million shares or 42.90% more from 20.56 million shares in 2017Q2 were reported.
Gp One Trading Lp invested 0.01% in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH). Illinois-based Northern Trust Corporation has invested 0% in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH). State Common Retirement Fund reported 33,000 shares. Metropolitan Life Communication New York stated it has 0% of its portfolio in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH). State Street Corp invested 0% of its portfolio in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH). Voya Mngmt Limited Liability Company invested 0% in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH). Invesco Ltd owns 51,639 shares. Moreover, Aqr Cap Limited Liability Corp has 0% invested in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH). Blackrock Inc stated it has 0% of its portfolio in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH). Deutsche Commercial Bank Ag holds 82,429 shares or 0% of its portfolio. Federated Invsts Pa holds 0% or 157,192 shares in its portfolio. Canada Pension Plan Inv Board holds 2.55M shares. Axa has invested 0.01% in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH). Tudor Invest Corporation Et Al reported 0.02% in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH). The Florida-based State Board Of Administration Of Florida Retirement System has invested 0% in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH).

Since August 17, 2017, it had 0 insider purchases, and 3 sales for $203,932 activity.

Analysts expect Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) to report $-0.64 EPS on March, 14.They anticipate $0.03 EPS change or 4.92 % from last quarter’s $-0.61 EPS. After having $-0.63 EPS previously, Tetraphase Pharmaceuticals, Inc.’s analysts see 1.59 % EPS growth. The stock increased 1.40% or $0.03 during the last trading session, reaching $2.18. About 3.03M shares traded or 299.63% up from the average. Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) has risen 106.58% since February 15, 2017 and is uptrending. It has outperformed by 89.88% the S&P500.

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Ratings Coverage

Among 15 analysts covering Tetraphase Pharmaceuticals (NASDAQ:TTPH), 6 have Buy rating, 0 Sell and 9 Hold. Therefore 40% are positive. Tetraphase Pharmaceuticals had 29 analyst reports since August 6, 2015 according to SRatingsIntel. The stock of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) earned “Outperform” rating by BMO Capital Markets on Wednesday, July 26. On Wednesday, September 9 the stock rating was downgraded by Wedbush to “Neutral”. The rating was maintained by SunTrust on Wednesday, February 14 with “Buy”. Needham maintained Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) on Friday, September 15 with “Hold” rating. Robert W. Baird downgraded Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) rating on Wednesday, September 9. Robert W. Baird has “Neutral” rating and $10 target. The stock of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) earned “Neutral” rating by Gabelli on Friday, May 13. The stock has “Buy” rating by Brean Capital on Thursday, August 6. BMO Capital Markets maintained it with “Buy” rating and $11.7600 target in Wednesday, June 21 report. Stifel Nicolaus upgraded the shares of TTPH in report on Wednesday, July 26 to “Buy” rating. The stock has “Buy” rating by SunTrust on Thursday, November 19.

Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company has market cap of $112.48 million. The Company’s lead product candidate is eravacycline, an intravenous and oral antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections. It currently has negative earnings. The firm has completed a Phase III clinical trial of eravacycline with intravenous administration for the treatment of complicated intra-abdominal infections; and initiated a Phase III clinical trial of eravacycline for the treatment of complicated urinary tract infections with intravenous-to- oral transition therapy.

Another recent and important Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) news was published by Nasdaq.com which published an article titled: “Mid-Day Market Update: US Stocks Turn Higher; Tetraphase Pharmaceuticals …” on February 14, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.